{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:12:03Z","timestamp":1788019923121,"version":"build-2784847793"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Programma Straordinario Oncologia\u2014Ministero della Salute"},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["10068"],"award-info":[{"award-number":["10068"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title>\n               <jats:p>Evaluate the frequency of trastuzumab-related serious cardiac events in clinical practice. Assess the cumulative incidence of cardiac disorders at 1, 2, and 3 years after first administration, irrespective of drug discontinuation. Identify predictors for the onset of cardiotoxicity.<\/jats:p>","DOI":"10.1634\/theoncologist.2013-0065","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T06:59:21Z","timestamp":1372921161000},"page":"795-801","source":"Crossref","is-referenced-by-count":36,"title":["Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study"],"prefix":"10.1093","volume":"18","author":[{"given":"Martina","family":"Bonifazi","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Franchi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Milan, Italy;"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Public Health, University of Milan, Milan, Italy;"},{"name":"Unit of Clinical Epidemiology, Galeazzi Orthopedic Institute, IRCCS, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, S. Maugeri Foundation, IRCCS, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zambon","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Epidemiology, Department of Statistics, University of Milano-Bicocca, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Epidemiology, Department of Statistics, University of Milano-Bicocca, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"La Vecchia","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Milan, Italy;"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Zocchetti","sequence":"additional","affiliation":[{"name":"Operative Unit of Territorial Health Service, Health Directorate, Regione Lombardia, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Negri","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,3]]},"reference":[{"key":"2021122308355401500_B1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"2021122308355401500_B2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel v-erbB-related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"key":"2021122308355401500_B3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"2021122308355401500_B4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1990.8.1.103","article-title":"Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer","volume":"8","author":"Paik","year":"1990","journal-title":"J Clin Oncol"},{"key":"2021122308355401500_B5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122308355401500_B6","volume-title":"Estensione delle indicazioni terapeutiche della specialita' medicinale Herceptin (trastuzumab), autorizzata con decisione della Commissione europea in data 22 maggio 2006 (Determinazione\/C n. 100\/2006)","author":"Agenzia Italiana del Farmaco."},{"key":"2021122308355401500_B7","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122308355401500_B8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"key":"2021122308355401500_B9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122308355401500_B10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1130-6343(09)72165-8","article-title":"Cardiotoxicity associated with trastuzumab in normal clinical practice","volume":"33","author":"Vicente","year":"2009","journal-title":"Farm Hosp"},{"key":"2021122308355401500_B11","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/annonc\/mds127","article-title":"Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis","volume":"23","author":"Tarantini","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122308355401500_B12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2021122308355401500_B13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1634\/theoncologist.2011-0184","article-title":"Bevacizumab in clinical practice: Prescribing appropriateness relative to national indications and safety","volume":"17","author":"Bonifazi","year":"2012","journal-title":"The Oncologist"},{"key":"2021122308355401500_B14","first-page":"119","volume-title":"Giornale Italiano di Health Technology Assessment","author":"Ragazzo","year":"2009"},{"key":"2021122308355401500_B15","volume-title":"Diagnosis related groups: A practitioner's guide","author":"Grimaldi","year":"1983"},{"key":"2021122308355401500_B16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.atherosclerosis.2011.04.014","article-title":"Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases","volume":"217","author":"Corrao","year":"2011","journal-title":"Atherosclerosis"},{"key":"2021122308355401500_B17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00228-010-0939-6","article-title":"Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: A population-based cohort study in Italy","volume":"67","author":"Corrao","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"2021122308355401500_B18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","article-title":"Better compliance to antihypertensive medications reduces cardiovascular risk","volume":"29","author":"Corrao","year":"2011","journal-title":"J Hypertens"},{"key":"2021122308355401500_B19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","article-title":"Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study","volume":"117","author":"Wadhwa","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308355401500_B20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc070065","article-title":"Cardiotoxicity of trastuzumab in clinical practice","volume":"357","author":"McArthur","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308355401500_B21","volume-title":"Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","author":"New York Heart Association","year":"1973"},{"key":"2021122308355401500_B22","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308355401500_B23","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"key":"2021122308355401500_B24","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","article-title":"Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes","volume":"273","author":"Zhao","year":"1998","journal-title":"J Biol Chem"},{"key":"2021122308355401500_B25","volume-title":"Linee guida neoplasia della mammella","author":"Associazione Italiana di Oncologia Medica."},{"key":"2021122308355401500_B26","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308355401500_B27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308355401500_B28","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1371\/journal.pmed.0030341","article-title":"Patient outcomes with teaching versus nonteaching healthcare: A systematic review","volume":"3","author":"Papanikolaou","year":"2006","journal-title":"PLoS Med"},{"key":"2021122308355401500_B29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.breast.2010.11.002","article-title":"Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues","volume":"20","author":"Zambelli","year":"2011","journal-title":"Breast"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/7\/795\/41856948\/oncolo_18_7_795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/7\/795\/41856948\/oncolo_18_7_795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:52:43Z","timestamp":1640307163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/7\/795\/6410264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,3]]},"published-print":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0065","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,7,1]]},"published":{"date-parts":[[2013,7,1]]}}}